Skip to content

Transarterial Radioembolization for Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria: A Single-Center Retrospective Cohort Study.

Oct 2026 · Journal of Vascular and Interventional Radiology · pp. 109108 · 0 citations
Medicine

TL;DR

In this single-center retrospective cohort of patients with HCC beyond the Up-to-Seven criteria, favorable tumor control and survival outcomes were observed after TARE, and 22.3% of patients subsequently underwent curative-intent surgery.

Abstract

Purpose

To describe clinical outcomes after transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) beyond the Up-to-Seven criteria.

Materials And Methods

This retrospective study included 94 treatment-naïve patients with HCC beyond the Up-to-Seven criteria who underwent TARE between November 2021 and December 2025. Outcomes included tumor response, local tumor progression-free survival (LTPFS), progression-free survival (PFS), overall survival (OS), and adverse events.

Results

The median maximum tumor diameter was 9.5 cm (interquartile range, 7.1-11.4 cm). A single lesion was observed in 55 (58.5%) patients, 30 (31.9%) had oligonodular disease, and 9 (9.6%) had ≥5 lesions. Index-lesion complete response (CR) and objective response rate (ORR) were 38.3% and 83.0%, respectively; at the patient level, CR and ORR were 38.3% and 81.9%, respectively. Median index-lesion LTPFS, patient-level LTPFS, PFS, and OS were 19.6, 15.7, 11.1, and 30.5 months, respectively. Low tumor-absorbed dose (TAD) was independently associated with worse OS (adjusted hazard ratio, 2.70; p = 0.016). Twenty-one patients (22.3%) subsequently underwent curative-intent surgery after TARE, with a more favorable OS pattern observed in the postsurgery state in an exploratory time-varying analysis (p = 0.004). Three fatal adverse events occurred.

Conclusion

In this single-center retrospective cohort of patients with HCC beyond the Up-to-Seven criteria, favorable tumor control and survival outcomes were observed after TARE, and 22.3% of patients subsequently underwent curative-intent surgery. Higher TAD was associated with longer OS, although this finding should be interpreted cautiously given the potential for confounding. Careful dosimetric planning is warranted given the observed fatal radiation pneumonitis events.

View source

Similar papers

Open access Sep 2026

Transarterial Radioembolization Versus Chemoembolization for Unresectable Large Single Hepatocellular Carcinoma

In patients with unresectable large solitary HCCs, TARE was associated with longer OS, improved local tumor control, and fewer serious adverse events than TACE, however, the survival advantage should be interpreted with caution.

M. Lee, Minuk Kim, Jayoun Kim et al. · 0 citations
Review Oct 2026

Yttrium-90 Radioembolization for High-Risk Hepatocellular Adenomas: A Single-Institution Experience.

PURPOSE To evaluate the safety and efficacy of Yttrium-90 (Y-90) transarterial radioembolization (TARE) for the treatment of high-risk hepatocellular adenomas (HCAs) at a single tertiary care center. MATERIALS AND METHODS A retrospective review was performed of all patients who underwent TARE for HCAs at a tertiary c...

N. Ji, A. Sher, Josh Kim et al. · 0 citations
Open access Oct 2026

CLINICAL AND TECHNICAL OUTCOMES OF TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER EXPERIENCE

Elevated AFP and PIVKA-II levels, multifocal involvement, and tumor size ≥ 5 cm were associated with advanced disease and high technical success and acceptable short-term safety of transarterial chemoembolization demonstrated high technical success and acceptable short-term safety.

A. Kozhamkul, A. Berkinbay, Y. Abilkhanov et al. · 0 citations
Open access Oct 2026

Preoperative radioembolization versus chemoembolization and upfront resection for resectable hepatocellular carcinoma beyond the Milan criteria.

BACKGROUND As the role of transarterial radioembolization (TARE) in resectable hepatocellular carcinoma (HCC) beyond Milan criteria remains undefined, this study compared preoperative TARE and chemoembolization (TACE) with primary resection to establish the optimal management strategy. MATERIALS AND METHODS We retros...

Jea-Yong Park, G. Lim, Yun-Mi Ko et al. · 0 citations
Open access Oct 2026

Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study.

Background To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC). Methods This single-center retrospective cohort study enrolled consecutive pa...

Zi-Zhuo Wang, Bai-Lu Wu, Chun-Shu Wu et al. · 0 citations
Review Open access Sep 2026

Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes

Few studies support modified radiation lobectomy (mRL) as a bridge to curative resection. This retrospective study reviews outcomes after mRL. Patients with primary hepatic tumors undergoing mRL 90Y radioembolization to grow the future liver remnant (FLR) were reviewed. Outcomes included tumor response, FLR kinetics, t...

M. Malavia, Jonathan Lindquist, K. Marchak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.